Cellectis (CLLS) Capital Expenditures (2015 - 2026)
Cellectis' (CLLS) quarterly Capital Expenditures came in at -$265000.0 in Q1 2026, up 32.91% year-on-year from -$199381.0 in Q1 2025, and down 106.25% quarter-over-quarter from $4.2 million in Q4 2025.
Cellectis (CLLS) Capital Expenditures (2015 - 2026) Analysis & Trends
Cellectis' Capital Expenditures history runs 12 years deep, the most recent figure standing at -$265000.0 for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 32.91% year-over-year to -$265000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 3.49% increase from a year earlier, with the FY2025 full-year figure at $2.4 million, down 8.63% from the prior year.
- Capital Expenditures eased to -$265000.0 in Q1 2026 per CLLS's latest filing, from $4.2 million in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.6 million in Q4 2024 and bottomed at -$1.2 million in Q3 2025.
- The 5-year median for Capital Expenditures is -$305000.0 (2025), against an average of $481294.1.
- Biggest YoY gain for Capital Expenditures was 146.84% in 2024; the steepest drop was 284.44% in 2024.
- Year by year, Capital Expenditures stood at $4.4 million in 2022, then slumped by 57.69% to $1.9 million in 2023, then soared by 146.84% to $4.6 million in 2024, then decreased by 8.12% to $4.2 million in 2025, then sank by 106.25% to -$265000.0 in 2026.
- Per Business Quant, the three latest CLLS Capital Expenditures figures stand at -$265000.0 (Q1 2026), $4.2 million (Q4 2025), and -$1.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Cellectis | 281.48 Mn | 95.81 Mn | - | -265,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -265,000.00 |
| Mar 31, 2026 | -265,000.00 |
| Dec 31, 2025 | 4.24 Mn |
| Dec 31, 2025 | 4.24 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Sep 30, 2025 | -1.18 Mn |
| Jun 30, 2025 | -305,000.00 |
| Jun 30, 2025 | -305,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Mar 31, 2025 | -395,000.00 |
| Dec 31, 2024 | 4.62 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | -777,000.00 |
| Sep 30, 2024 | -777,000.00 |
| Jun 30, 2024 | -1.04 Mn |
| Jun 30, 2024 | -1.04 Mn |
| Mar 31, 2024 | -218,000.00 |
| Mar 31, 2024 | -218,000.00 |
| Dec 31, 2023 | 1.87 Mn |
| Dec 31, 2023 | 1.87 Mn |